Evidence types
Basic science articles covering early-stage IBD research, disease mechanisms, lab findings, microbiome work, genetics, and experimental models.
Page 14 of 15 · 707 articles
ER stress in intestinal epithelial cells is proposed as a key molecular mechanism in UC development; targeting ER pathways (notably IRE1β) could eventually lead to new treatments that strengthen the gut barrier and...
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease, Colorectal cancer, and Research and clinical trials. The original article is from Cell Cycle.
People with Crohn’s may be interested because the study links oxidative stress and specific genes to disease activity, which could inform future biomarkers or treatments. It helps explain biological pathways behind...
A new NIR-II-emitting MOF probe could enable deeper, higher-contrast fluorescence imaging of inflamed gut tissue and might be developed as a targeted delivery/imaging agent relevant to IBD research and future...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Toxicology Mechanisms...
The study identifies candidate metabolites that may underlie gut–brain biochemical crosstalk during colitis, which could point to early biomarkers or mechanistic targets relevant to IBD-related brain effects.
The study identifies a cellular mechanism by which arctigenin reduced inflammatory macrophage death and improved colitis in mice, suggesting a potential new target (macrophage FAO → GSDMD) for therapies or...
If true, a common gut microbe (Fusobacterium nucleatum) and its metabolite succinic acid could worsen intestinal inflammation by changing macrophage behavior, suggesting new targets to reduce flares or mucosal injury in...
The study suggests dietary tryptophan might reduce bacterial-induced acute lung injury in the context of colitis by altering gut–lung immune signaling, which could be relevant to IBD patients who are at risk for...
This study identifies molecular targets and organoid-based effects of ganoderic acid A on inflammatory pathways relevant to IBD, pointing to a potential multi-target avenue for future drug-discovery research.
JAK1 inhibitors are an established therapeutic pathway in IBD; new, more selective small molecules could expand future treatment options. This study reports a novel compound with strong preclinical activity against...
This preclinical study suggests a fermented postbiotic product may protect the colon in a mouse model of ulcerative colitis by altering the microbiome and tryptophan metabolites and by reducing ferroptotic cell death....
The study presents a mitochondria-targeted compound that reduced necrosis markers, HMGB1, and IL-1β in cell and mouse colitis models, highlighting a potential new pathway for IBD treatment research.
This study describes a new nanozyme approach that reduced inflammation and shifted the gut microbiome in mouse colitis models, suggesting a potential future strategy to boost probiotic therapy for IBD by targeting...
Researchers are exploring plant-based formulas for inflammation beyond the gut. If the SGD effects translate to humans, it could point to new ways to prevent or treat liver injury that can accompany active UC by...
The paper identifies Candida albicans–reactive Th17 cells that travel between oral and gut mucosa and become more pathogenic in Crohn’s disease, suggesting a fungal–immune link that could matter for disease mechanisms...
The study identifies a previously unrecognized protein (TNFAIP1) that appears to promote inflammation in ulcerative colitis and proposes a compound (Salidroside) that directly binds and inhibits it in lab and mouse...
New targeted delivery approaches aim to concentrate therapy in the gut lining and inflamed areas, which could improve effectiveness and reduce systemic side effects for people with IBD.
Macrophages and innate immune signaling are central to how gut inflammation starts and persists in IBD; better understanding these pathways could point to new treatment strategies for people whose disease doesn’t fully...
People with IBD may have overlapping genetic and cellular features with other autoimmune liver diseases like primary biliary cholangitis; understanding shared biology could eventually improve disease monitoring or point...
The study describes a new oral-delivery microsphere that improved loading and gut-targeted release of celastrol and showed beneficial effects in a mouse colitis model and on gut microbiota. If translatable, this approach...
This study points to a specific immune pathway (IRF5 repressing S100A9) that controls suppressive granulocytic MDSCs in ulcerative colitis, suggesting a new target for therapies aimed at modulating harmful inflammation.
This study identifies an immune pathway (IDO–AhR) that a parasite-derived antigen appears to activate to reduce experimental colitis in mice. That pathway is relevant because it helps explain how immune regulation might...
The work models how Mycobacterium avium can provoke epithelial inflammation similar to Crohn's disease, pointing to possible molecular links between infection and CD-like pathology that could guide future research.
Researchers are exploring methods to make probiotic therapies more stable through the digestive tract and to deliver anti-inflammatory molecules directly where intestinal inflammation produces high reactive oxygen...
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
The study describes new small molecules that target IL‑6 and NF‑κB and showed anti-inflammatory effects in laboratory and mouse colitis models, signaling a potential early-stage drug-discovery direction relevant to IBD...
This study shows a mechanism by which IL-10 protects gut epithelial mitochondria and barrier function during exposure to an IBD-associated E. coli strain, which could be relevant to understanding pathways that maintain...
Researchers are exploring microbiome-derived molecules as targeted, locally acting therapies for ulcerative colitis that might avoid systemic immunosuppression. EB1010 showed anti-inflammatory activity and...
The study suggests a new host-directed mechanism that helps a common beneficial gut bacterium (Faecalibacterium prausnitzii) colonize and protect the gut lining, and identifies heparan sulfate as a potential way to...
People with long-standing ulcerative colitis face an increased risk of colorectal cancer; this study highlights PPARGC1A as a gene that may be downregulated early in that progression, which could eventually help identify...
Researchers used machine learning to prioritize microbiome-related regulatory targets in Crohn's disease, which may guide future lab and clinical research into microbial pathways (like butyrate-related metabolism) that...
The study links a common commensal fungus, Candida albicans, to a focused Th17 immune response that can turn harmful in Crohn’s disease, identifying a specific cell population that could be targeted more precisely than...
The study targets oxidative stress and the TXNIP/NLRP3 inflammasome axis, both implicated in IBD inflammation and barrier damage. If translatable, nanozyme-assisted probiotic therapy could offer a novel, targeted way to...
A natural compound (C3G) reduced inflammation and changed gut bacteria and metabolites in an experimental colitis model, pointing to possible new mechanisms or leads for IBD therapies.
The finding links a specific mucus-associated protein (HMGB1) to barrier defects in Crohn’s disease, which could help explain how bacteria reach and inflame tissue in active lesions and point to future biomarker or...
Phosphatidylcholines are implicated in IBD biology; identifying a gene that regulates PC metabolism could point to new mechanistic targets. If PRKAB1 modulates epithelial lipid metabolism relevant to inflammation, it may...
The paper suggests a mechanistic link between gut microbial gas production and mitochondrial function, which could be relevant for understanding metabolic stress and inflammation in IBD.
The study identifies a potential biologic approach (macrophage-derived exosomes) that improved epithelial repair and barrier function in a mouse colitis model, which could inform future therapeutic research for IBD.
The work targets oxidative/nitrosative stress and mucosal repair—mechanisms important in IBD—using a novel delivery vehicle that pairs an approved anti-inflammatory drug with catalytic cerium ions. If translated, this...
Understanding how commensal-specific CD8+ T cells are generated and become pathogenic could reveal new mechanisms contributing to IBD, pointing to future therapeutic targets. The project aims to clarify immune–microbiota...
FUT enzymes affect mucosal immunity and have been associated with Crohn's disease and other IBDs; understanding their function could reveal new biological mechanisms and future therapeutic targets.
This study presents an engineered probiotic delivery platform that could improve survival and targeted action of live microbial therapies for IBD, potentially reducing local inflammation while affecting the gut...
Researchers are exploring new ways to deliver regenerative factors and reshape the gut microbiome in IBD.
Researchers identify a gut microbe (Sutterella species) that may worsen intestinal inflammation by blocking AhR-driven IL-22 and IL-17 responses—pathways that help protect the gut lining.
IBD is increasingly linked with anxiety, depression, and cognitive symptoms; this study suggests gut microbes may change tryptophan metabolism in colitis and contribute to those brain-related symptoms, which could point...
This study describes a new oral immunoproteasome inhibitor (ent-F10) with preclinical activity in animal models of ulcerative colitis and rheumatoid arthritis, highlighting a potential new drug-development direction that...
This paper links specific features of the gut bacterial flagellome to TLR5-driven immune activation and reports a disease-associated shift in flagellin profiles in Crohn’s disease and ulcerative colitis, suggesting...
